Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

7.790 +0.100 (+1.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
Earnings Outlook For Mind Medicine
Via Benzinga
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
From MindMed
Via Business Wire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
3 High-Growth Penny Stocks to Consider Buying in April 2023
Here are three high-growth penny stocks long-term investors may want to keep on their watch list, or buy, in April. 
Via InvestorPlace
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management
In this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ: MNMD), Robert Barrow. 
Via Benzinga
MindMed to Participate in May Investor Conferences
From MindMed
Via Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
Via Benzinga
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
From MindMed
Via Business Wire
Psychedelic Stock Gainers And Losers From April 17, 2023
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive... 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday. 
Via Benzinga
Why Is Ocugen (OCGN) Stock Moving Today?
Ocugen (OCGN) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial. 
Via InvestorPlace
US Stocks Mixed; Retail Sales Drop 1% In March
U.S. stocks traded mixed this morning, following the release of economic reports. Following the market opening Friday, the Dow traded up 0.08% to 34,055.40 while the NASDAQ fell 0.10% to 12,153.84. The... 
Via Benzinga
Why Is Mind Medicine (MNMD) Stock Up 26% Today?
Mind Medicine (MNMD) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial of lysergide (LSD). 
Via InvestorPlace
MindMed Reveals Topline Data From Mid-Stage Depression Study Evaluating Lysergide
Mind Medicine Inc's (NASDAQ: MNMD) collaborators have released topline data from a double-blind, investigator-initiated trial evaluating lysergide major depressive disorder (MDD). 
Via Benzinga
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
From MindMed
Via Business Wire
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
From MindMed
Via Business Wire
Psychedelic Stock Gainers And Losers From April 12, 2023
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.